라인에이지 셀 테라퓨틱스(LCTX)는 NYSE MKT에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $1.02 (-0.97%), 시가총액 $0.32B, 52주 최저~최고 $0.65 ~ $1.96.
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; and OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries. It also offers ReSonance (ANP1), an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of sensor
라인에이지 셀 테라퓨틱스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
라인에이지 셀 테라퓨틱스의 현재 주가는 $1.02 (-0.97%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
라인에이지 셀 테라퓨틱스의 시가총액은 약 $0.32B입니다.
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company